TapImmune and Marker Therapeutics merge to create new I/O company

TapImmune has snapped up privately-owned Marker Therapeutics to create a new company based on a non-genetically engineered, multi-antigen T cell therapy platform. Described as a "merger of equals", the stockholders of each company will own around half of the combined company.